Florida Department of HealthEPI UPDATE

A weekly publication by the Bureau of Epidemiology

 

April 13, 2001

"The reason for collecting, analyzing and disseminating information on a disease is to control that disease. Collection and analysis should not be allowed to consume resources if action does not follow."

--Foege WH et al. Int. J of Epidemiology 1976; 5:29-37.

Richard S. Hopkins, MD, MSPH, Bureau Chief, State Epidemiologist

Don Ward, Surveillance Section Administrator, Epi Update Managing Editor

Jason Glisson, BS, Epi Editorial Assistant

Bureau of Epidemiology Frequent Contributors:

Steven Wiersma, MD, MPH,

Deputy State Epidemiologist

Jodi Baldy, MPH,

Biological Scientist IV

Ursula E. Bauer, PhD,

Chronic Disease Epidemiologist

Lisa Conti, DVM, MPH,

State Public Health Veterinarian

Regional Epidemiologists:

Dolly Katz, PhD, MPH,

SE Florida

Roger Sanderson, RN, MA,

SW Florida

Carina Blackmore, MS Vet. Med., PhD,

NE Florida Carina Blackmore, MS Vet. Med., PhD,

Zuber Mulla, MSPH,

Central Florida Carina Blackmore, MS Vet. Med., PhD,

Please print out this material and share with epidemiology staff, county health department directors, administrators, medical directors, nursing directors, environmental health directors and others with an interest in information of this type. Thank you.

The Bureau of Epidemiology is available 24 hours a day, 7 days a week for consultation at our main number (SunCom 205-4401 or 850/245-4401) PLEASE NOTE: Consultation after 5 p.m. & on weekends is intended for emergencies.

The Department of Health has a home on the World Wide Web at http://www.doh.state.fl.us

In this issue:

1. National Shortage of Adult Td and TT Vaccines and Potential Shortage of DTaP Vaccine

2. Outbreak of Acute Respiratory Febrile Illness Among College Students -- Acapulco, Mexico, March 2001

3. Rabies Bytes

4. Weekly Disease Table


 

1. National Shortage of Adult Td and TT Vaccines and Potential Shortage of DTaP Vaccine

Henry T. Janowski, MPH, Chief, Bureau of Immunization

As many of you are aware, there is a national shortage of adult Tetanus and Diphtheria Toxoids (Td) and Tetanus Toxoid (TT) vaccines; and a potential shortage of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccines. The following information is provided to assist you in managing the anticipated supplies of these vaccines, necessary for prophylaxis in wound management.

Attached is a copy of the Notice to Readers: Update on the Supply of Tetanus and Diphtheria Toxoids and of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Morbidity and Mortality Weekly Report (MMWR), March 16, 2001 / Volume 50(10) / Pages 189-190. The Notice to Readers can also be found on the Centers for Disease Control and Prevention’s (CDC) Web site at http://www.cdc.gov/mmwr//preview/mmwrhtml/mm5010a3.htm.

Nationwide Shortage of Adult Td and TT Vaccines:

Aventis Pasteur is now the sole nationwide distributor of Td and TT. They are shipping limited quantities of these vaccines to assure a wide distribution of available doses. While the company is increasing its production, the shortage is not expected to be resolved for 12 to 18 months. Wound care in clinics and hospitals continues to be the priority for Td and TT and this priority will remain in effect until adequate supplies are restored. Clinics and hospitals in need of vaccine for wound care should call Aventis Pasteur at 1-800-VACCINE or 1-800-822-2463.

Potential Nationwide Shortage of DTaP Vaccine:

There is a potential shortage of DTaP to vaccinate all children. On March 7, 2001, the Food and Drug Administration (FDA) approved a newly formulated version of Aventis Pasteur’s Tripedia® in one-dose vials without preservative and with only a trace amount of thimerosal. With approval of this vaccine, the supply of DTaP should gradually improve.

Presently, there is no change in the national policy for the recommended DTaP immunization schedule.

The CDC is working closely with State Health Departments to ensure equitable distribution of available DTaP vaccine. The CDC and the FDA are monitoring the DTaP vaccine supply situation closely and will provide more guidance should significant supply problems occur.

If an insufficient supply of DTaP vaccine does develop, priority should be given to vaccinating infants with the three initial doses of DTaP since pertussis is most severe among children less than one year of age. If rationing becomes necessary, the fourth DTaP dose should be deferred. The CDC is recommending that the fourth dose-and not the fifth dose-be deferred because the preschool booster is important for maintaining immunity against diphtheria, tetanus and pertussis during the early elementary school years. Receipt of a primary series of DTaP confers adequate protection during the second year of life for many children, so the fourth dose is considered to be the safest to temporarily postpone. When adequate DTaP supplies are available, all children who did not receive the fourth DTaP dose should be recalled for vaccination.

If you have any questions regarding this information, please contact your local county health department.

 

 

2. Outbreak of Acute Respiratory Febrile Illness Among College Students --- Acapulco, Mexico, March 2001

Steven Wiersma, MD, MPH, Deputy State Epidemiologist

An outbreak, believed to be due to histoplasmosis, has been identified among travelers to Acapulco, Mexico. A case is defined as an acute respiratory febrile illness characterized by fever for at least 3 days and one or more of the following symptoms: cough, shortness of breath, chest pain, or headache in a student who visited Acapulco during March 2001. A MMWR describing details is available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5014a1.htm>. At this time, one Florida case is under investigation. We encourage readers to get the word out to health care providers that see college students and other travelers. If you identify a potential case, please call Dr. Steven Wiersma at telephone (850) 245-4411, SunCom 205-4411, or email Steven_Wiersma@doh.state.fl.us for information on testing and reporting.

 

 

3. Rabies Bytes

By Dr. Lisa Conti, State Public Health Veterinarian

Animal Rabies Up for the First Quarter of 2001

Compared with the first quarter (Q1) in 2000, reported animal rabies increased more than 50% during Q1 2001. This was largely due to an epizootic in Seminole County with 10 of the 49 rabid animals reported January through March 2001. Nineteen additional counties reported from one to four animals. During Q1 2000, 32 animals were reported -- Polk County reported 5 and 17 additional counties reported from 1 to 3 rabid animals.

Rabid Animal

Q1 2001

Number %

Q1 2000

Number %

Raccoon

34

69

27

84

Cat

7

14

1

3

Fox

6

12

1

3

Bat

1

2

1

3

Horse

1

2

   

Otter

   

1

3

TOTAL

49

100

32

100

Of the seven cats reported during Q1 2001, all were reported with neurologic signs including "extreme aggressiveness" and "sick, injured kitten." Five were pet cats and only one was vaccinated against rabies; however, this adult cat was found as a stray and administered vaccine for the first time less than one month prior to its onset of neurologic signs. Three of the cats were from Duval County; and one each from Clay, Martin, Lee and Broward counties. The Q1 2001 rabid horse was reported from Seminole County. It was unvaccinated against rabies and was maintained in a paddock with several other horses and goats, all of which required 180-days quarantine after the rabies diagnosis. State regulations require vaccination of all dogs, cats and ferrets and recommend vaccination of horses against rabies.

PEP Reporting a Useful Tool for Rabies Program Evaluation

Animal bites and other potential rabies exposures are required to be reported to the counties. Among these reports, since October 2000 county health departments have been submitting information on people for whom rabies postexposure prophylaxis (PEP) was given or recommended, and on monkey bites. The former provides important rabies program evaluation information for local and state use and the latter to aid with determining if herpes B testing is indicated.

In a few short months of reviewing rabies PEP forms, several lessons have been learned. We would like to regularly highlight such informative cases to stimulate further dialogue with the objective of identifying useful strategies for program improvement.

The Emergency Department (ED) that is Quick with the Needle

Several counties have encountered the situation where the ED has begun PEP for a dog- or cat-bite victim when the animal was locatable for a 10-day observation period. Reasons for this include:

  1. Detailed animal bite history was not taken: "Who owns the animal?" or "Is the animal available for observation?"
  2. Animal control was not contacted or no animal control exists in the county
  3. Patients were so anxious about rabies that they insisted on beginning rabies PEP.
  4. Others

County health department strategies for improving this situation include: providing rabies training in-services for their ED; requiring a check-off sheet for the ED that stimulates asking appropriate questions, including – "Has animal control been notified?" and suggesting the ED administer just the rabies vaccine for day 0 with the county health department to follow-up with human rabies immune globulin (must be given before day 7) if in fact the dog or cat is not available.

Please email your comments about this problem and suggestions for improvement to lisa_conti@doh.state.fl.us.

For information about rabies in Florida, please see the Bureau of Epidemiology website at: http://www.doh.state.fl.us/disease_ctrl/epi/htopics/popups/rabies.htm

 

 

4. Weekly Disease Table (Week 14)

DISEASE

1999 TO
WEEK 14

2000 TO
WEEK 14

3-YEAR
AVERAGE
TO WEEK 14*

2000
TOTAL
CASES

2001 TO
WEEK 14

2001
WEEK 14
ONLY

Animal Rabies

40

33

45

161

56

7

Anthrax

0

0

0

0

0

0

Botulism, foodborne

0

0

0

0

0

0

Botulism, infant

0

0

0

0

0

0

Botulism, wound

0

0

0

0

0

0

Botulism, other

0

0

0

0

0

0

Brucellosis

0

0

0.3

2

1

0

Campylobacteriosis

181

169

161.3

1025

157

22

Ciguatera

0

0

0

14

0

0

Cryptosporidiosis

16

10

16.3

180

17

2

Cyclosporiasis

0

1

1

9

21

0

Dengue Fever

1

0

0.7

5

1

0

Diphtheria

0

0

0

0

0

0

Ehrlichiosis, human

0

0

0

0

0

0

Encephalitis, chickenpox

0

0

0

0

0

0

Encephalitis, Eastern Equine

0

0

0

0

0

0

Encephalitis, herpes

2

1

2

7

0

0

Encephalitis, influenza

0

1

0.3

1

0

0

Encephalitis, measles

0

0

0

0

0

0

Encephalitis, mumps

0

0

0

0

0

0

Encephalitis, other

1

1

0.7

8

1

0

Encephalitis, St. Louis

0

0

0

0

0

0

Encephalitis, Venezuelan

0

0

0

0

0

0

Encephalitis, Western Equine

0

0

0

0

0

0

Escherichia Coli 0157:H7

9

7

6.3

96

5

1

Escherichia Coli, other

6

2

3.3

14

1

0

Giardiasis

193

208

216.7

1466

170

22

H. Influenzae Cellulitis

0

0

0.3

1

0

0

H. Influenzae Epiglottitis

0

0

0

1

0

0

H. Influenzae Meningitis

5

1

3.3

11

3

0

H. Influenzae Pneumonia

2

2

2.3

8

8

0

H. Influenzae Prim.Bacteremia

3

12

7

57

26

2

H. Influenzae Septic Arthritis

0

0

0

1

0

0

Hantaviris Infection

0

0

0

0

0

0

Hemolytic Uremic Syndrome

1

2

1

17

1

0

Hemorrhagic Fever

0

0

0

0

0

0

Hepatitis A

147

128

136.3

592

138

9

Hepatitis B

72

76

70.7

528

78

10

Hepatitis B (+HbsAg in pregnant women)

5

61

22

493

60

5

Hepatitis, Perinatal Hep B

0

0

0

1

1

1

Hepatitis C

7

4

3.7

21

5

1

Hepatitis, Non-A, Non-B

0

3

7

6

1

0

Hepatitis, Other, including unspecified

2

4

2

7

3

0

Lead Poisoning

359

278

336

1223

133

17

Legionellosis

6

11

9.7

52

8

0

Leprosy

0

0

0.7

4

0

0

Leptospirosis

0

0

0

2

0

0

Listeriosis

5

6

3.7

32

6

0

Lyme Disease

2

2

3

55

0

0

Malaria

20

13

15.7

90

11

0

Measles

1

0

0.7

2

0

0

Meningitis, Group B Strep

5

5

4

21

3

1

Meningitis, List Monocytogenes

2

1

1.7

7

0

0

Meningitis, Meningococcal

13

8

11

41

26

0

Meningitis, other

14

21

15.3

110

10

0

Meningitis, Strep Pneumoniae

37

38

37

110

22

0

Meningococcemia, disseminated

20

23

24.7

81

15

0

Mercury Poisoning

1

1

0.7

11

0

0

Mumps

1

0

1

4

0

0

Neurotoxic Shellfish Poisoning

0

0

0

0

0

0

Pertussis

7

7

8.3

48

4

0

Plague, Bubonic

0

0

0

0

0

0

Plague, Pneumonic

0

0

0

0

0

0

Poliomyelitis

0

0

0

0

0

0

Psittacosis

0

0

0

3

0

0

Q Fever

0

0

0

0

0

0

Human Rabies

0

0

0

0

0

0

Rocky Mountain Spotted Fever

1

0

0.7

1

1

0

Rubella

0

1

0.3

2

0

0

Rubella, Congenital

0

0

0

1

0

0

Salmonellosis

355

314

331

2756

341

31

Shigellosis

338

302

308.7

1295

134

7

Smallpox

0

0

0

0

0

0

Staphylococcus Aureus (GISA/VISA)

0

0

0

0

0

0

Staphylococcus Aureus (GRSA/VRSA)

0

0

0

0

0

0

Streptococcal Disease, Invasive Group A

11

39

21

150

41

1

Streptococcus Pneumoniae, Invasive

159

282

199

1149

328

34

Tetanus

1

0

0.7

1

0

0

Toxoplasmosis

3

2

3

12

0

0

Trichinosis

0

0

0

1

0

0

Tularemia

0

0

0

0

0

0

Typhoid Fever

15

1

7

12

2

0

Vibrio Alginolyticus

2

1

1.3

15

0

0

Vibrio Cholerae Type 01

0

0

0

0

0

0

Vibrio Cholerae Non-01

2

1

1.3

4

0

0

Vibrio Fluvialis

1

0

0.3

2

0

0

Vibrio Hollisae

1

3

1.7

3

0

0

Vibrio Mimicus

1

1

0.7

2

0

0

Vibrio, other

0

0

0

2

0

0

Vibrio Parahaemolyticus

1

1

1

16

0

0

Vibrio Vulnificus

2

0

1

13

0

0

Yellow Fever

0

0

0

0

0

0


* The column of data representing the "3-year average to week ##" is the average of years 1998, 1999 and 2000 cases to the current listed week (##).